Document:

EX-10.14

 Exhibit 10.14 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TOA CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

FIRST AMENDMENT TO 
 SIDE
LETTER AGREEMENT 
 This First Amendment to Side Letter Agreement (this “Amendment”) is entered into effective as of
the last signature date hereto (the “Amendment Effective Date”), by and between Biomet 3i, LLC (successor and assignee of Zimmer Dental, Inc.), a Florida limited liability company (“Biomet 3i”), and RTI Surgical,
Inc. (formerly RTI Biologics, Inc.), a Delaware corporation (“RTI”). 
 Recitals 

A. Biomet 3i and RTI are parties to a Side Letter Agreement to Exclusive Distribution Agreement dated as of March 29, 2016 (the
“Side Letter Agreement”). 
 B. Biomet 3i and RTI desire to amend the Side Letter Agreement, subject to and in accordance
with the terms and conditions set forth in this Amendment. 
 C. Unless otherwise defined herein, capitalized terms used in this Amendment
shall have the meanings given to them in the Side Letter Agreement. 
 Agreement 

In consideration of the mutual covenants contained in this Amendment, the Side Letter Agreement and the Distribution Agreement, as well as
other good and valuable consideration, the adequacy and sufficiency of such consideration being hereby agreed to and acknowledged, Biomet 3i and RTI hereby agree as follows: 

1. DS Territory. Recital B of the Side Letter Agreement is hereby amended to expand the DS Territory to include the [****]. As of the
Amendment Effective Date, the term “DS Territory” shall mean [****]. 
 2. Cut-off
Times. The table in Section 1(b) of the Side Letter Agreement is hereby replaced in its entirety with the following: 
 [****] 

*All times are stated in the local time of [****]. 

3. Effect of Amendment. Except as specifically amended above, the Side Letter Agreement and the Distribution Agreement shall remain in
full force and effect and are hereby ratified and confirmed. 
 4. Applicable Law. This Amendment shall be governed by and construed
in accordance with the laws of the State of Illinois, without regard to its choice of law rules. 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TOA CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

*                *       
         * 
 IN WITNESS WHEREOF, each Party has caused this Amendment to be executed by its
respective duly authorized representative as of the Amendment Effective Date. 
  

			
	RTI SURGICAL, INC.
		
	By:	 	/s/ Robert P. Jordheim
	
	Name: Robert P. Jordheim
	
	Title: Executive Vice President & CFO

 
			
		
	Date:	 	November 4, 2016

  

			
	BIOMET 3i, LLC
		
	By:	 	/s/ David Josza

 
			
		
	Name:	 	David Josza

 
			
		
	Title:	 	General Manager, Dental

 
			
		
	Date:	 	November 7, 2016

  
 -2-EX-10.15

 Exhibit 10.15 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 
  

 
 January ___, 2017 

RTI Surgical, Inc. 
 Attn: Chief Financial Officer 

11621 Research Circle 
 Alachua, Florida 32615 

Re: Letter Agreement for Sharing Certain Expenses 

To Whom It May Concern: 
 Reference is made to
the Exclusive Distribution Agreement made and entered into between Zimmer Dental, Inc. (“Zimmer”) and RTI Biologics, Inc. (“RTI”) as of September 30, 2010 (as amended, the “Distribution Agreement”). Defined terms
that are used but not defined in this letter agreement shall have the meanings given to them in the Distribution Agreement. 
 The Parties
desire to enter into this letter agreement in order to memorialize their respective commitments to share in certain expenses as follows: 

1.    Marketing Approval in [****]. RTI is seeking Marketing Approval in [****] for the following Implants (the
“Subject Implants”): [****]. RTI’s good faith estimate of its anticipated costs and expenses associated with seeking the Marketing Approval is [****]. As reimbursement for RTI’s costs and expenses in connection with RTI seeking
such Marketing Approval, Zimmer shall pay to RTI the amount of its costs and expenses, estimated to be [****], as follows: (i) [****] shall be paid within [****] from RTI’s execution of this letter agreement; (ii) an amount equal to
the application fees required for the Marketing Approval shall be paid within [****] from RTI’s notice to Zimmer that the application(s) is ready for submission (and, in any event, prior to RTI’s submission of the application(s)); and
(iii) an amount equal to RTI’s remaining costs and expenses, which, along with (i) and (ii), is not estimated to exceed [****], shall be paid within [****] from RTI’s invoice for such remaining costs and expenses. In lieu of the
payment schedule set forth above, Zimmer may choose (in its sole discretion) to pre-pay RTI for its estimated costs and expenses. If RTI’s costs and expenses in connection with RTI seeking the Marketing
Approval are anticipated to exceed [****], the Parties agree that RTI will present the additional costs and expenses to Zimmer and, prior to RTI incurring such costs and expenses, 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 
Zimmer will authorize and agree to reimburse RTI for such additional costs and expenses. RTI makes no guarantee that the Regulatory Authority will grant Marketing Approval for the Subject
Implants. The Parties agree that RTI’s costs and expenses (for which Zimmer will reimburse RTI) include without limitation:(1) regulatory consulting services performed by RTI employees or third-party contractors; and (2) audit costs
incurred by RTI that would not have been incurred by RTI but for RTI’s seeking Marketing Approval for the Subject Implants. 

2.    [****] Study. Zimmer is sponsoring a clinical study in [****]. RTI has: (1) provided Implants for use in
the study; (2) will continue to provide such Implants for use in the study; and (3) [****]. Upon completion of the study, Zimmer shall notify RTI in writing and RTI shall pay to Zimmer, as partial reimbursement for Zimmer’s costs and
expenses in connection with such study, an amount equal to [****] within [****] from RTI’s receipt of such notice. 

3.    [****] Study. Zimmer is sponsoring a clinical study conducted through [****]. As partial reimbursement for
Zimmer’s costs and expenses in connection with such study, RTI shall pay to Zimmer an amount equal to [****] as follows: (i) [****] shall be paid within [****] from RTI’s execution of this letter agreement, and (ii) [****] shall be paid
within [****] from the date that Zimmer notifies RTI in writing that such study has been completed. 
 Terms and conditions regarding venue
and choice of Jaw shall be the same as in the Distribution Agreement, with such terms and conditions incorporated herein by reference. The symbol “$” means United States dollars. 

If the provisions above are acceptable to RTI, please execute this letter agreement in the space below and return a signed copy to my
attention. 

  
 - 2 - 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 
			
	 Sincerely,

	
	 Zimmer Dental, Inc.

		
	By:	 	/s/ Adam R. Johnson

 
			
		
	Name:	 	Adam R. Johnson

 
			
		
	Title:	 	Group President

 
			
		
	Date:	 	2/6/2017

  

			
	 Acknowledged and agreed

	
	RTI Surgical, Inc.
		
	By:	 	/s/ Roger Rose

			
		
	Name:	 	Roger Rose

			
		
	Title:	 	Executive Vice President

			
		
	Date:	 	2/7/2017

  

			
	cc:	  	RTI Surgical, Inc.
		  	Attn: General Counsel
		  	11621 Research Circle
		  	Alachua, FL 32615

  
 - 3 -EX-10.16

 Exhibit 10.16 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 
  

 
 

 
 June 28, 2018 
 RTI Surgical,
Inc. 
 11621 Research Circle 
 Alachua, Florida 32615 

Attn: Chief Financial Officer 

Re:    Letter Agreement re: Marketing Approval in [****] 

To Whom It May Concern: 
 Reference is made to
(i) the Exclusive Distribution Agreement made and entered into between Biomet 3i LLC (‘ZBD’) and RTI Surgical, Inc. (‘RTI’) as of September 30, 2010 (as amended, the ‘Distribution Agreement’), and
(ii) the letter agreement dated January 31, 2017, between ZBD to RTI concerning, among other things, Marketing Approvals in [****] (the ‘2017 Letter Agreement’). Defined terms that are used but not defined in this letter
agreement shall have the meanings given to them in the 2017 Letter Agreement. 
 The Parties hereby agree that paragraph 1 in the 2017
Letter Agreement (with the heading ‘Marketing Approval in [****]) is null and void, and that the Parties are hereby released from any obligations set forth in such paragraph including, without limitation, RTI’s obligations to seek
Marketing Approvals for the Subject Implants in [****], and ZBD’s obligation to reimburse RTI for certain costs and expenses in connection therewith. The Parties may, but shall not be required to, reevaluate at a later date opportunities for
seeking Marketing Approvals for the Subject Implants in [****]. 
 Except as specifically set forth above, the 2017 Letter Agreement and the
Distribution Agreement shall remain in full force and effect and are hereby ratified and confirmed. This letter agreement shall be governed by and construed in accordance with the laws of the State of Illinois, without regard to its choice of law
rules. 
 [Remainder of page intentionally left blank; 

Signatures appear on following page] 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 If the provisions above are acceptable to RTI, please execute this letter agreement in the
space below and return a signed copy to ZBD. 
  

			
	 Sincerely,

	
	 Biomet 3i LLC

		
	By:	 	/s/ C.M. Jayashankar
		
	Name:	 	C.M. Jayashankar
		
	Title:	 	Marketing Director
		
	Date:	 	June 29, 2018

  

			
	 Acknowledged and agreed:

	
	 RTI Surgical, Inc.

		
	By:	 	/s/ Olivier M. Visa
		
	Name:	 	Olivier M. Visa
		
	Title:	 	Vice President OEM, Sports and Donor Services
		
	Date:	 	July 9, 2018

  

			
	cc:	  	Corporate Counsel
		  	RTI Surgical, Inc.
		  	11621 Research Circle
		  	Alachua, FL 32615

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]